-
DO ELITE CONTROLLERS REQUIRE ART FOR SECONDARY BENEFITS?
Clinical Infectious Diseases, May 2019 There is an ongoing debate in the literature about whether elite controllers require antiretroviral therapy (ART) for secondary benefits, including control for low-level viral replication and reduction of inflammation.
May 25, 2019
-
Lancet Digital Health, May 2019 (ACTG) A5288 (MULTI-OCTAVE) is one of the first studies to look at interventions for medication adherence in lower-income and middle-income countries (LMICs) for individuals failing second line therapy.
May 01, 2019
-
NWCS 399: CT AS NON-INVASIVE ASSESSMENT OF FAT QUALITY
The Journal of Clinical Endocrinology & Metabolism, April 2019 Fat quality or function contributes to risk for diseases such as heart disease, fatty liver disease, and diabetes, and may be as important as fat quantity when assessing the risk of poor health outcomes.
Apr 11, 2019
-
UNDERLYING FACTORS ASSOCIATED WITH RACIAL DISPARITIES IN HIV OUTCOMES
Open Forum Infectious Diseases, February 2019 Racial/ethnic disparities in HIV outcomes have persisted despite effective antiretroviral therapy.
Feb 01, 2019
-
DTG/3TC IS DURABLE INITIAL THERAPY THROUGH 48 WEEKS
Journal of Antimicrobial Chemotherapy, January 2019 This study is an important subset analysis of the AIDS Clinical Trials Group study A5353, which demonstrated the efficacy and safety of dolutegravir and lamivudine for the initial treatment of HIV-1 infection at week 24 in individuals with HIV-1 RNA levels 1000-500 000 copies/mL for the first time.
Jan 18, 2019
